Drug Approvals

FDA approves Tresiba, Ryzodeg for diabetes treatment

FDA approves Tresiba, Ryzodeg for diabetes treatment

The FDA has approved two new treatments, Tresiba and Ryzodeg, for both type 1 and type 2 diabetes.

FDA approves second nonstatin drug to treat patients with high cholesterol

FDA approves second nonstatin drug to treat patients with high cholesterol

The drug is approved for patients who are unable to control their LDL cholesterol with current treatment options.

Oxycontin for 11-year-olds? I'm okay with it

Oxycontin for 11-year-olds? I'm okay with it

By

The FDA approval of a pediatric indication for Oxycontin creates a safer situation for terminally ill children.

OxyContin approved for children aged 11 and older

OxyContin approved for children aged 11 and older

The FDA has approved a pediatric indication for OxyContin in patients as young as 11 years.

Nonsurgical weight loss procedure receives FDA approval

Nonsurgical weight loss procedure receives FDA approval

An intragastric balloon receives approval as a non-surgical weight loss procedure for patients with mild-to-moderate obesity.

FDA approves two new therapies for irritable bowel syndrome

FDA approves two new therapies for irritable bowel syndrome

Two new therapies to treat irritable bowel syndrome, eluxadoline and rifaximin, have been approved by the FDA.

Raplixa approved to help control surgical bleeding

Raplixa approved to help control surgical bleeding

Spray-dried fibrin sealant promotes clotting when other methods are "ineffective or impractical."

FDA approves expands use of diabetic retinopathy drug

FDA approves expands use of diabetic retinopathy drug

The FDA has granted expanded the use of Eylea injection to treat diabetic retinopathy in patients with diabetic macular edema (DME).

Cresemba approved for serious fungal infections

Cresemba approved for serious fungal infections

New drug targets cell walls of the fungi and is available in oral and intravenous formulations.

First internal use tissue adhesive earns FDA approval

First internal use tissue adhesive earns FDA approval

The FDA has approved Cohera Medical's TissuGlu Surgical Adhesive, the first tissue adhesive for internal use.

Empagliflozin/linagliptin tablets approved for type 2 diabetes

Empagliflozin/linagliptin tablets approved for type 2 diabetes

The FDA has approved empagliflozin/linagliptin tablets as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments.

First generic esomeprazole approved by FDA

First generic esomeprazole approved by FDA

The FDA has approved esomeprazole magnesium delayed-release capsules, the first generic version of AstraZeneca's Nexium.

Novel combo hypertension drug gets FDA nod

Novel combo hypertension drug gets FDA nod

Perindopril arginine and amlodipine besylate may be used as initial therapy if a patient is likely to need multiple drugs to achieve their blood pressure goals.

Secukinumab earns FDA approval for plaque psoriasis

Secukinumab earns FDA approval for plaque psoriasis

Secukinumab has been approved by the FDA for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Novel anticoagulant Savaysa gets FDA nod

Novel anticoagulant Savaysa gets FDA nod

Savaysa (edoxaban) is indicated to treat deep vein thrombosis and pulmonary embolism and prevent stroke.

Saxenda earns FDA approval for weight management

Saxenda earns FDA approval for weight management

The FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management.

Peramivir earns FDA approval to ease flu symptoms in adults

Peramivir earns FDA approval to ease flu symptoms in adults

Patients given paramivir had flu symptoms ease 21 hours sooner compared with patients left untreated.

FDA approves first meningococcal B vaccine

FDA approves first meningococcal B vaccine

The FDA has approved Trumenba, the first vaccine approved in the U.S. to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B

Novel weight-loss medication approved by the FDA

Novel weight-loss medication approved by the FDA

Results showed that patients who took Contrave had an average weight loss of 4.1% more compared with patients who were assigned placebo.

Oritavancin is approved to treat skin infections

Oritavancin is approved to treat skin infections

The FDA has approved three drugs to treat ABSSI in 2014.

Empagliflozin approved to treat diabetes

Empagliflozin approved to treat diabetes

Pivotal trials showed that empagliflozin improved hemoglobin A1c levels compared with placebo.

FDA approves extended-release painkiller

FDA approves extended-release painkiller

The medication is designed to deter abuse of the drug by snorting or injection.

FDA approves inhaled insulin drug Afrezza

FDA approves inhaled insulin drug Afrezza

Afrezza can be used for the improvement of glycemic control in adult patients with diabetes mellitus.

FDA approves tedizolid phosphate for skin infections

FDA approves tedizolid phosphate for skin infections

The antibiotic is designed to treat infections including MRSA.

Brodalumab effective for moderate to severe psoriasis

Brodalumab effective for moderate to severe psoriasis

By

Brodalumab binds to the IL-17 receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor.

Vedolizumab approved to treat ulcerative colitis, Crohn disease

Vedolizumab approved to treat ulcerative colitis, Crohn disease

The FDA has approved vedolizumab for patients with inadequate response to conventional therapies.

FDA approves Otezla for psoriatic arthritis

FDA approves Otezla for psoriatic arthritis

By

Diarrhea, nausea and headache were the most common side effects observed in patients treated with apremilast.

FDA reviews OTC Singulair use

FDA reviews OTC Singulair use

Inappropriate use in children under 15 years old and patients seeking relief for asthma cited as top concerns.

Second oral tablet approved for grass allergies

Second oral tablet approved for grass allergies

By

Merck's Grastek becomes the second sublingual treatment for grass pollen-induced allergic rhinitis with or without conjunctivitis.

First sublingual tablet for grass allergies approved

First sublingual tablet for grass allergies approved

The FDA has cleared the once-daily tablet Oralair to treat grass-pollen induced allergic rhinitis with or without conjunctivitis.

Sign Up for Free e-newsletters